Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.

Clinical epigenetics - 23 Oct 2020

Zhang Mu-Chen, Fang Ying, Wang Li, Cheng Shu, Fu Di, He Yang, Zhao Yan, Wang Chao-Fu, Jiang Xu-Feng, Song Qi, Xu Peng-Peng, Zhao Wei-Li

Abstract excerpt

BACKGROUND: Elderly patients with diffuse large B-cell lymphoma (DLBCL) present with poor clinical outcome and intolerance to intensive chemotherapy. Histone deacetylase inhibitors (HDACIs) show anti-lymphoma activities and can be applied to treat DLBCL. This study aimed to evaluate efficacy and safety of oral HDACI tucidinostat (formerly known as chidamide) plus R-CHOP (CR-CHOP) in elderly patients with newly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CREB-Binding Protein
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to E1A-Associated p300 Protein

Share to Histone Deacetylase Inhibitors

Share to Prednisone

Share to Rituximab

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 33097085
DOI: 10.1186/s13148-020-00948-9
PMCID: PMC7585299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.PMID 33097085Read ↗

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Semantic proximity Read ↗

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Semantic proximity Read ↗

Targeting HDACs for diffuse large B-cell lymphoma therapySemantic proximity Read ↗

TP53 mutations predict poor prognosis in diffuse large B-cell lymphoma: A single-center studySemantic proximity Read ↗

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].Semantic proximity Read ↗

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Diffuse large B-cell lymphoma: current standard treatment and future perspectives.Semantic proximity Read ↗

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

A53-Adapted Decitabine-Containing R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Defined by LymphGen: Preliminary Results of a Prospective Proof-of-Concept StudySemantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.